A5049859852- Psoriasis: Treatment and Pathogenesis
- Spondyloarthritis Studies and Treatments
- Dermatology and Skin Diseases
- Autoimmune and Inflammatory Disorders Research
- Rheumatoid Arthritis Research and Therapies
- Autoimmune Bullous Skin Diseases
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical studies and practices
- Asthma and respiratory diseases
- Hidradenitis Suppurativa and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Cytokine Signaling Pathways and Interactions
- Colorectal and Anal Carcinomas
- T-cell and B-cell Immunology
- Immunotherapy and Immune Responses
- Immunodeficiency and Autoimmune Disorders
- Systemic Lupus Erythematosus Research
- Cutaneous lymphoproliferative disorders research
- Urticaria and Related Conditions
- melanin and skin pigmentation
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Complementary and Alternative Medicine Studies
- Nail Diseases and Treatments
- Microscopic Colitis
- Mast cells and histamine
Icahn School of Medicine at Mount Sinai
1998-2025
UCB Pharma (United Kingdom)
2025
Mount Sinai Hospital
2024
Mount Sinai Hospital
2019-2023
American Academy of Dermatology
2015-2022
Mount Sinai Beth Israel
2021
Novartis (Germany)
2021
Toronto Western Hospital
2017-2021
Krembil Research Institute
2017-2021
AbbVie (United States)
2014-2021
Inflammatory cytokines such as tumor necrosis factor (TNF) have been implicated in the pathogenesis of psoriasis. We evaluated safety and efficacy etanercept, a TNF antagonist, for treatment plaque psoriasis.In this 24-week, double-blind study, 672 patients underwent randomization 652 either received placebo or etanercept subcutaneously at low dose (25 mg once weekly), medium twice high (50 weekly). After 12 weeks, group began twice-weekly with 25 etanercept. The primary measure clinical...
Objective To update the 2009 Group for Research and Assessment of Psoriasis Psoriatic Arthritis (GRAPPA) treatment recommendations spectrum manifestations affecting patients with psoriatic arthritis (PsA). Methods GRAPPA rheumatologists, dermatologists, PsA drafted overarching principles management PsA, based on consensus achieved at face‐to‐face meetings via online surveys. We conducted literature reviews regarding key domains (arthritis, spondylitis, enthesitis, dactylitis, skin disease,...
Psoriasis is a common papulosquamous skin disease. The histopathology characterized by epidermal hyperplasia and inflammation. Recent studies suggest that keratinocyte proliferation inflammation in psoriasis are manifestations of the same underlying pathological process. Interleukin 6 (IL-6), cytokine major mediator host response to tissue injury infection, produced both keratinocytes leukocytes culture. IL-6 expression was studied psoriatic plaques immunoperoxidase staining with two...
Hidradenitis suppurativa is a painful, chronic inflammatory skin disease with few options for effective treatment. In phase 2 trial, adalimumab, an antibody against tumor necrosis factor α, showed efficacy hidradenitis suppurativa.PIONEER I and II were similarly designed, 3 multicenter trials of adalimumab suppurativa, two double-blind, placebo-controlled periods. period 1, patients randomly assigned in 1:1 ratio to 40 mg weekly or matching placebo 12 weeks. 2, reassigned at every-other-week...
<h3>Objective</h3> Assess ustekinumab efficacy (week 24/week 52) and safety 16/week 60) in patients with active psoriatic arthritis (PsA) despite treatment conventional and/or biological anti-tumour necrosis factor (TNF) agents. <h3>Methods</h3> In this phase 3, multicentre, placebo-controlled trial, 312 adults PsA were randomised (stratified by site, weight (≤100 kg/>100 kg), methotrexate use) to 45 mg or 90 at week 0, 4, q12 weeks placebo 16 crossover 24, 28 40. At 16, <5%...
Objective: To determine safety and efficacy of monotherapy
The interleukin‐17 cytokine family plays a central role in psoriasis pathogenesis. To evaluate the efficacy and safety of brodalumab, human anti‐interleukin‐17 receptor antibody, treating patients with moderate‐to‐severe plaque psoriasis. In this phase III, double‐blind, placebo‐controlled study (NCT01708590; AMAGINE‐1), adult U.S.A., Canada Europe were randomized to brodalumab (140 or 210 mg) placebo every 2 weeks (Q2W), an additional dose at week 1, for 12‐week induction phase. At 12,...
Objective To develop an evidence‐based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between American College Rheumatology ( ACR ) National Psoriasis Foundation NPF ). Methods We identified critical outcomes in PsA clinically relevant PICO (population/intervention/comparator/outcomes) questions. A Literature Review Team performed systematic literature review to summarize evidence supporting benefits harms available therapies...